Core Viewpoint - Hagens Berman is urging investors of Primo Brands Corporation (PRMB) to take action regarding a securities fraud class action lawsuit, which alleges that the company misled investors about the successful integration of its merger, leading to significant operational failures and a substantial drop in stock value [1]. Summary by Relevant Sections Key Allegations & Facts - The class period for the lawsuit is from June 17, 2024, to November 6, 2025 [1]. - The lead plaintiff deadline is set for January 12, 2026 [1]. - Core allegations include misleading statements regarding the merger integration being "flawless," while concealing severe technology failures and supply disruptions that resulted in customer losses and a CEO replacement [1]. - Following the disclosure of operational failures on November 6, 2025, the stock price fell approximately 36% [1]. Financial Impact - The stock price decline occurred after the company admitted to moving "too far too fast" on various integration work streams, confirming operational failures [1]. - The need to slash 2025 revenue forecasts was also disclosed, contributing to the stock's dramatic drop [1]. Next Steps for Investors - Investors who purchased securities of Primo Brands (PRMB) or Primo Water (PRMW) during the class period and suffered losses may be eligible to serve as Lead Plaintiff [1]. - The deadline for filing a motion for Lead Plaintiff is January 12, 2026 [1].

Core Viewpoint - aTyr Pharma, Inc. is facing a securities class action lawsuit due to a significant stock drop of 83% following the failure of its drug trial for Efzofitimod, which did not meet its primary endpoint [1][2]. Company Overview - The lawsuit alleges that aTyr and its executives provided materially false and misleading information regarding the efficacy of Efzofitimod, leading to inflated stock prices [2]. - The firm Hagens Berman is leading the litigation and emphasizes the importance of accurate representation of clinical trial data in biotech securities cases [3]. Legal Allegations - The core issue revolves around whether aTyr misrepresented the drug's ability to help patients taper off steroid usage, a critical measure of efficacy [3][5]. - The complaint highlights a gap between the company's optimistic public statements and the actual performance of Efzofitimod in the Phase 3 EFZO-FIT study [4]. Financial Impact - Following the announcement of the trial results, aTyr's stock plummeted from $6.03 to $1.02, reflecting an 83.2% loss on September 15, 2025 [5]. - Investors who purchased shares during the class period (November 7, 2024, through September 12, 2025) and suffered losses are encouraged to submit their claims [6]. Next Steps for Investors - Hagens Berman has a history of securing over $2.9 billion in settlements for investors and is advising affected investors to act before the lead plaintiff deadline of December 8, 2025 [6].

Core Viewpoint - The lawsuit against Stride, Inc. alleges that the company misled investors regarding its operational health and compliance, leading to a significant stock crash of over 54% following damaging disclosures [1][4]. Summary by Relevant Sections Allegations - Stride is accused of inflating enrollment figures by retaining "ghost students" and failing to disclose operational and compliance failures, which artificially inflated its stock price [2][7]. - The company allegedly ignored compliance by increasing student-to-teacher ratios beyond required limits and neglecting mandated special education services [7]. Key Events - On September 14, 2025, a lawsuit by Gallup-McKinley school district surfaced, alleging fraud and deceptive practices, causing Stride's stock to plunge by 11% [7]. - On October 28, 2025, Stride announced Q1 fiscal 2026 results, revealing severe operational issues due to a failed platform upgrade, leading to a stock crash of over 54% in one day [7]. Investor Information - Investors who purchased Stride, Inc. securities during the class period from October 22, 2024, to October 28, 2025, and suffered losses may be eligible to serve as Lead Plaintiff, with a deadline to file by January 12, 2026 [5][7].

Core Viewpoint - MoonLake Immunotherapeutics has faced a significant decline in share price, dropping nearly 90% in one day due to disappointing Phase 3 trial results for its drug candidate sonelokimab (SLK) [1][5]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing SLK, which is intended to treat moderate to severe hidradenitis suppurativa (HS), a chronic inflammatory skin disease [3]. Legal Issues - A securities fraud class action lawsuit has been filed against MoonLake in the U.S. District Court for the Southern District of New York, alleging that the company and certain executives made materially false and misleading statements regarding SLK's clinical prospects [2][4]. - The lawsuit claims that MoonLake exaggerated SLK's benefits over competitors, particularly in relation to its unique "Nanobody" structure, which was presented as a major competitive advantage [4][6]. Trial Results - The VELA Phase 3 trials, particularly VELA-2, did not meet their primary endpoint, leading to a significant drop in stock price from $61.99 to $6.24, a decrease of $55.75 per share [5]. - Analysts noted that the efficacy results from the successful trial were substantially lower than those achieved by the competitor drug BIMZELX, which shares the same molecular targets [4][6]. Investor Impact - The decline in stock price has prompted Hagens Berman, a plaintiffs' rights firm, to investigate claims of misleading information that may have artificially inflated the stock price during the class period from March 10, 2024, to September 29, 2025 [2][6].

Accessibility StatementSkip Navigation SAN FRANCISCO, Nov. 18, 2025 /PRNewswire/ -- A new class action complaint has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) and certain of its top executives, significantly enlarging the alleged class period covered by the ongoing securities litigation. The suits allege that aTyr and its top executives made false and misleading statements about the efficacy of its drug, Efzofitimod, leading investors to purchase stock at artificially inflated prices. At the heart ...

Core Viewpoint - A securities class action lawsuit has been filed against Primo Brands Corporation following its problematic merger with BlueTriton Brands, alleging misleading statements regarding the merger's success and integration process [1][10]. Summary by Sections Lawsuit Details - The lawsuit aims to represent investors who acquired Primo Brands' common stock between June 17, 2024, and November 6, 2025, and is being investigated by prominent shareholder rights law firm Hagens Berman [2][3]. - The litigation focuses on claims that Primo's assurances about the merger accelerating growth and achieving operational efficiencies were false, as the integration was reportedly going poorly [3][5]. Financial Impact - Investors began to realize the issues on August 7, 2025, when Primo announced its Q2 2025 results, leading to a share price drop of $2.41 (-9%) after the then-CEO acknowledged disruptions in product supply and service [3][6]. - On November 6, 2025, the company announced a significant leadership change, with CEO Robbert Rietbroek being forced out, and revealed a drastic cut in its 2025 revenue forecast from expected growth to a low single-digit decline [4][5]. Market Reaction - Following the announcement of the leadership change and the revised revenue forecast, Primo's share price plummeted by $8.20 (-36%) the next day, reflecting investor concerns over the merger's integration issues [6][5]. Investigation Focus - The investigation by Hagens Berman is centered on whether company leadership was aware of the integration problems that contradicted their public assurances [7].

Core Viewpoint - Soleno Therapeutics, Inc. experienced a significant drop in share price by $18.78 (-28%) following disappointing news regarding its drug VYKAT™ XR, which is intended to treat hyperphagia associated with Prader-Willi syndrome [1][2]. Company Performance - The company had previously assured investors of a successful launch of VYKAT™ XR after receiving FDA approval, stating that the launch "has been going really well" and "definitely exceeded our expectations" [2]. - However, during the Q3 2025 earnings call, Soleno disclosed a disruption in the launch trajectory, citing a lower number of start forms and increased discontinuations due to non-serious adverse events [2]. Market Reaction - Following the negative news, Soleno's share price fell nearly 40% from August 14, 2025, to November 5, 2025 [4]. - The market reaction was influenced by concerns raised by short seller Scorpion Capital, which highlighted potential risks associated with VYKAT™ XR, including reports of children hospitalized for heart failure after using the drug [3][4]. Investigations and Allegations - Hagens Berman, a national shareholders rights firm, is investigating whether Soleno misled investors regarding the commercial prospects of VYKAT™ XR [5]. - Scorpion Capital characterized Soleno as a "one-trick pony" with no other significant assets or pipeline, raising doubts about the company's future if VYKAT™ XR fails [3][4]. - Allegations were made regarding the integrity of clinical trial data and the influence of a controversial physician involved in key trials, suggesting potential irregularities in the company's disclosures [4].

Core Points - A securities fraud class action has been filed against Synopsys, Inc. for allegedly misleading investors regarding its customer risks and growth prospects, following disappointing Q3 2025 financial results [1][2][4] - The lawsuit covers the period from December 4, 2024, to September 10, 2025, and claims that Synopsys made false statements about the sustainability of revenue growth in its Design IP business [3][4] - Synopsys reported a Q3 2025 EPS of $1.50, a 45% decline year-over-year and a 33% decline sequentially, primarily due to an 8% drop in Design IP revenues [5] Company Overview - Synopsys, Inc. provides silicon design, IP, simulation, and analysis solutions, operating in two segments: Design IP and Design Automation [3] - The Design IP segment includes various IP products and services, which are critical for minimizing integration risk and expediting customer adoption of new technologies [4][5] Financial Impact - Following the announcement of disappointing financial results, Synopsys shares plummeted by $216.59, representing a 35% decrease on September 10, 2025, marking the worst single-day decline since the company went public in 1992 [2][5] - The lawsuit alleges that the company's focus on AI customers, which require more customization, negatively impacted the economics of its Design IP business [5]

Core Viewpoint - MoonLake Immunotherapeutics faced a significant decline in share price following the announcement of disappointing Phase 3 trial results for its product candidate sonelokimab (SLK), leading to a securities class action lawsuit alleging misleading statements about the drug's efficacy and trial design [1][2][6]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on treating skin inflammatory diseases, specifically targeting cytokines IL-17A and IL-17F [3][4]. Trial Results and Market Reaction - The Phase 3 trial results revealed that only one of the two trials achieved statistical significance, with the efficacy of SLK being substantially lower than that of the competitor's FDA-approved product, BIMZELX [6]. - Following the announcement on September 28, 2025, MoonLake's share price plummeted by $55.75, approximately 90%, on September 29, 2025 [2][6]. Allegations of Misleading Statements - The lawsuit claims that MoonLake made false and misleading statements regarding SLK's advantages over BIMZELX, including assertions about superior efficacy and the unique benefits of its Nanobody structure [5][6]. - Specific allegations include misleading information about the clinical benefits of SLK compared to traditional monoclonal antibodies and the expected clinical efficacy based on its structural advantages [5]. Legal Proceedings - A securities class action has been filed against MoonLake, with a focus on the company's statements about SLK's trial design and efficacy data [1][3]. - The lead plaintiff deadline for the class action is set for December 15, 2025, and the firm Hagens Berman is actively seeking investors who suffered losses to participate in the lawsuit [3][6].

Core Viewpoint - A class-action lawsuit has been filed against KBR, Inc. alleging misleading statements made by the company prior to the cancellation of a significant military contract, which adversely affected its business outlook [1][2]. Group 1: Lawsuit Details - The lawsuit targets KBR investors who acquired securities between May 6, 2025, and June 19, 2025, and seeks to represent those who suffered substantial losses [2]. - The legal action claims that KBR executives provided an overly optimistic outlook on a crucial partnership just before its collapse [2]. Group 2: Contract Cancellation Impact - The lawsuit arises from the U.S. Department of Defense's cancellation of its global household goods contract with HomeSafe Alliance LLC, a joint venture led by KBR, announced on June 20, 2025 [3]. - Following the contract termination, KBR shares dropped over 7% due to the loss of a contract valued at up to $20 billion over a potential nine-year term [3]. Group 3: Misrepresentation Allegations - On May 6, 2025, during its Q1 earnings call, KBR assured investors that the HomeSafe partnership was "strong" and projected a mid-point revenue contribution of about $400 million for 2025 [4]. - Just weeks later, on June 19, 2025, HomeSafe disclosed the termination of the contract for cause, attributed to operational issues, which KBR allegedly knew about but did not disclose to investors [5]. Group 4: Financial Revisions - After the contract termination, KBR revised its low-end 2025 revenue guidance downward by approximately $900 million (-9%) during its Q2 2025 financial results announcement on July 31, 2025 [6]. - KBR management acknowledged operational challenges during the earnings call, raising questions about whether the company intentionally misled investors regarding the contract's status [6].